Showing stat.MEShow all
2 papers · 1 filter
stat.ME2025
Cure Rate Joint Model for Time-to-Event Data and Longitudinal Tumor Burden with Potential Change Points
Yixiang Qu, Ethan M. Alt, Weibin Zhong +3
In non-small cell lung cancer (NSCLC) clinical trials, tumor burden (TB) is a key longitudinal biomarker for assessing treatment effects. Typically, standard-of-care (SOC) therapie…
stat.ME2024
Jointly modeling time-to-event and longitudinal data with individual-specific change points: a case study in modeling tumor burden
Ethan M. Alt, Yixiang Qu, Emily Damone +3
In oncology clinical trials, tumor burden (TB) stands as a crucial longitudinal biomarker, reflecting the toll a tumor takes on a patient's prognosis. With certain treatments, the…